GRZAN India Medical Device Registration Service

1. Key takeaways

GRZAN provides medical device manufacturers with end-to-end registration and licence-holding services for the Indian market. The service scope is designed around the actual procedures of India’s Medical Devices Rules, 2017 (G.S.R. 78(E)) and covers every stage from classification determination to post-market maintenance. The engagement is structured so that each phase of the Indian pathway — classification, dossier, legal document chain, licence holding, submission and post-market — has a defined owner, a defined deliverable and a defined place in the statutory timeline, rather than being assembled reactively as queries arrive.

• Market entry determination: product classification (notified-list search or a classification request to the CLA), pathway selection (Class A exemption from registration, the standard MD-14 route, or the no-predicate MD-27 route), and a Rule 36(3) six-country evidence inventory.
• Dossier preparation: the Device Master File (DMF, Annexure II of the Fourth Schedule), the Plant Master File (PMF, Annexure I of the Fourth Schedule), the essential principles checklist, labelling and IFU (Chapter VI, Rule 44), and IVD performance evaluation report organisation under the three-batch rule.
• Legal document chain: finalisation and co-signing of the Power of Attorney (PoA), notarisation, apostille or embassy authentication, and certified English translations of non-English documents.
• Licence holding: screening and verification of the Indian authorised agent (manufacturing licence, wholesale licence or MD-42), MD-41 to MD-42 wholesale registration, and licence-holding structure design with agreement terms covering document handover, termination rights and site endorsement.
• Submission and approval, then post-market: MD-14 filing with fee calculation, query responses, foreign site inspection handling, vigilance process setup, Rule 38(1)(ii) foreign-action monitoring, recall contingency planning, change management under the Sixth Schedule, the 5-year retention fee calendar and PSURs for no-predicate devices.

2. Legal basis

Every element of the service maps to a specific provision of the Indian framework, and the table below shows the mapping stage by stage. The design principle is that nothing in the service plan exists for its own sake: each deliverable answers a requirement that can be located in the rules, a schedule or published CDSCO practice.

The stage mapping also shows where the risks concentrate. The entry-determination row decides whether the project should proceed at all; the legal document chain and licence-holding rows carry the structural risks that are expensive to fix later; and the post-market row carries the recurring obligations that never end for as long as the licence is held.

3. Expert insights

Across six Southeast Asian markets, we operate our own entities. GRZAN maintains its own presence in Singapore, Malaysia, Thailand, Indonesia, Vietnam and the Philippines, and can serve directly as the client’s local licence holder, importer and authorised representative — not subcontracted to third parties. This is the structural difference between GRZAN and purely agency-based consultancies: the responsibilities of holding a licence on the client’s behalf are borne by the same organisation that advises on them, and there is no invisible layer between the client and the entity whose name is on the certificate.

In India, we apply the same self-controlled standard. The Indian market is delivered jointly by the GRZAN registration team and licensed local partners in India. We transplant the experience of building self-owned licence-holding structures in Southeast Asia into our Indian projects: the priority is to help the client build a controllable licence-holding structure, with the agent agreement always stipulating document handover obligations, termination rights and concentrated site endorsement arrangements, so that the client is never left without leverage if the relationship changes.

There are three things we do not do. We do not treat drafts as current rules; we do not promise approval timelines; and we do not accept market data without an official source. Every deadline, fee and obligation we publish can be located in a specific notification number and clause. This discipline costs something in marketing convenience, but it means the client’s project plan is never anchored to a figure that cannot be cited.

4. Practical recommendations

A typical project runs on the following rhythm, with the first month deliberately reserved for the questions that decide whether the project should proceed at all.

• The recommended first step is not signing an engagement but an access determination meeting: provide the product list (models, intended use, overseas registration status and the issuing authority of existing FSCs), and GRZAN issues an India Access Pathway Determination covering the classification conclusion, the pathway selection, the six-country threshold judgement, the fee calculation and the timeline estimate.
• Before entering India, secure the structural terms in the agent agreement — document handover, termination rights and site endorsement — while negotiating leverage still exists.
• Sequence the three-batch production and testing for IVDs early in the plan, because it sits on the manufacturing calendar rather than the regulatory one.
• Treat the post-licence items (customs package, vigilance process, retention fee calendar) as part of the project scope from month one, not as an afterthought once the certificate arrives.

The determination document is designed so that, before any decision to enter India is made, the critical uncertainties — classification, pathway, the six-country threshold, fees and duration — have already been resolved on paper, at a fraction of the cost of discovering them inside a live filing.

5. Verification checklist

• ☐ The Rule 36(3) six-country evidence inventory has been completed for every model
• ☐ The pathway (Class A exemption, MD-14 or MD-27) has been determined and documented
• ☐ The agent agreement contains document handover, termination and site endorsement terms
• ☐ The MD-41 to MD-42 wholesale registration status of the licence holder has been verified
• ☐ The 5-year retention fee date and the post-market obligations are entered in the maintenance calendar

Regulatory information verified as of 27 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including India. Our team prepares dossiers to CDSCO expectations, manages SUGAM submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com